Please use this identifier to cite or link to this item: http://hdl.handle.net/11452/34656
Full metadata record
DC FieldValueLanguage
dc.contributor.authorKocatürk, Emek-
dc.contributor.authorPırıl, Etikan-
dc.contributor.authorOktay, Taşkapan-
dc.contributor.authorNilgün, Atakan-
dc.contributor.authorTeoman, Erdem-
dc.contributor.authorSerap, Utaş-
dc.contributor.authorEkin, Savk-
dc.contributor.authorRafet, Koca-
dc.contributor.authorŞebnem, Aktan-
dc.date.accessioned2023-10-30T07:48:58Z-
dc.date.available2023-10-30T07:48:58Z-
dc.date.issued2017-09-09-
dc.identifier.citationKocatürk, E. vd. (2018). ''Turkish dermatologists' approach for chronic spontaneous urticaria: A questionnaire based study''. Dermatologica Sinica, 36(2), 70-74.en_US
dc.identifier.issn1027-8117-
dc.identifier.issn2223-330X-
dc.identifier.urihttps://doi.org/10.1016/j.dsi.2017.09.002-
dc.identifier.urihttps://www.sciencedirect.com/science/article/pii/S1027811717300903-
dc.identifier.urihttp://hdl.handle.net/11452/34656-
dc.description.abstractBackground/Objectives: Chronic spontaneous urticaria (CSU) is a common skin disorder which represents a challenge both for the patients and physicians. Guidelines and treatment algorithms have been created to help physicians to ease management. Our aim was to determine Turkish dermatologists' approach to CSU with regard to treatment, search for causative factors and use of instruments to assess the quality of life and severity of the disease. Methods: This was a cross-sectional methodological study which was performed by delivery of a questionnaire including ten questions about the management of CSU. Results: Analyses of 314 questionnaires revealed that the most common first-line treatments were non-sedating antihistamines in standard doses (65.6%), while second-line treatment was updosing antihistamines (59.9%) followed by addition of sedative-antihistamines (26.4%) and systemic steroids (19.1%). Third-line treatment option was omalizumab in 35% followed by systemic steroids. Twenty-two percent of the dermatologists referred the patients to a center experienced in urticaria. Most of them were performing laboratory testing for underlying causes including thyroid function tests, C-reactive protein, thyroid auto-antibodies, stool analyses, infection markers. Urticaria activity score and chronic urticaria quality of life questionnaire were used by 30 and 13%, respectively, while 56% were using none of the instruments. Conclusion: Our study showed that the therapeutic management of Turkish dermatologists was parallel to the European Urticaria Guidelines. The high utility of omalizumab as a third line regimen improved patient care. Nevertheless there is a need for centers experienced in urticaria to refer anti-histamineresistant patients where third-line treatment options can not be implemented.en_US
dc.language.isoenen_US
dc.publisherWolters Luver Medknow Publicationsen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.rightsAtıf Gayri Ticari Türetilemez 4.0 Uluslararasıtr_TR
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectDermatologyen_US
dc.subjectUrticariaen_US
dc.subjectDermatologistsen_US
dc.subjectTherapeuticsen_US
dc.subjectDiagnosisen_US
dc.subjectGuidelineen_US
dc.subjectChronic idiopathic urticariaen_US
dc.subjectManagementen_US
dc.subjectDiagnosisen_US
dc.subjectOmalizumaben_US
dc.subjectGuidelineen_US
dc.subjectLifeen_US
dc.titleTurkish dermatologists' approach for chronic spontaneous urticaria: A questionnaire based studyen_US
dc.typeArticleen_US
dc.identifier.wos000433284500002tr_TR
dc.identifier.scopus2-s2.0-85031672386tr_TR
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergitr_TR
dc.contributor.departmentUludağ Üniversitesi/Tıp Fakültesi/Dermatoloji ve Zührevi Hastalıklar Anabilim Dalı.tr_TR
dc.contributor.orcid0000-0002-0144-3263tr_TR
dc.identifier.startpage70tr_TR
dc.identifier.endpage74tr_TR
dc.identifier.volume36tr_TR
dc.identifier.issue2tr_TR
dc.relation.journalDermatologica Sinicaen_US
dc.contributor.buuauthorEmel, Bülbül Başkan-
dc.contributor.researcheridAAH-1388-2021tr_TR
dc.relation.collaborationYurt içitr_TR
dc.relation.collaborationSanayitr_TR
dc.subject.wosDermatologyen_US
dc.indexed.wosSCIEen_US
dc.indexed.scopusScopusen_US
dc.wos.quartileQ4en_US
dc.contributor.scopusid57196063450tr_TR
dc.subject.scopusOmalizumab; Urticaria; Non-Sedating Histamine H1 Antagonistsen_US
dc.subject.emtreeAntihistaminic agenten_US
dc.subject.emtreeC reactive proteinen_US
dc.subject.emtreeOmalizumaben_US
dc.subject.emtreeArticleen_US
dc.subject.emtreeChronic urticariaen_US
dc.subject.emtreeCross-sectional studyen_US
dc.subject.emtreeDermatologisten_US
dc.subject.emtreeDisease severityen_US
dc.subject.emtreeHealth care deliveryen_US
dc.subject.emtreeHumanen_US
dc.subject.emtreeLaboratory testen_US
dc.subject.emtreePractice guidelineen_US
dc.subject.emtreeQuality of lifeen_US
dc.subject.emtreeQuestionnaireen_US
dc.subject.emtreeThyroid function testen_US
dc.subject.emtreeTreatment outcomeen_US
Appears in Collections:Scopus
Web of Science

Files in This Item:
File Description SizeFormat 
Kocatürk_vd_2018.pdf185.94 kBAdobe PDFThumbnail
View/Open


This item is licensed under a Creative Commons License Creative Commons